Clinical Trials Browser

Phase 2 × Completed × radium Ra 223 dichloride × Clear all

Prostate Cancer Metastatic to Bone

NCT03002220 2024-12-11

EXCAAPE

Phase 2 Completed

52 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Phase 2 Completed

40 enrolled 18 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast

Breast Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

Phase 2 Completed

122 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

Phase 2 Completed

100 enrolled

Genitourinary

Hormone Refractory Prostate Cancer

NCT02346526 2022-09-29

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Phase 2 Completed

22 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Phase 2 Completed

45 enrolled 7 charts

Breast

Breast Neoplasms

NCT03062254 2021-09-21

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

Phase 2 Completed

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT02283749 2021-02-02

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

Phase 2 Completed

5 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02199197 2020-10-30

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Phase 2 Completed

49 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02034552 2019-07-23

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

Phase 2 Completed

68 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT02023697 2019-07-12

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

Phase 2 Completed

391 enrolled 53 charts

Genitourinary

Prostatic Neoplasms

NCT02390934 2019-06-11

RAD-THYR

Phase 2 Completed

13 enrolled

Head & Neck

Thyroid Neoplasms

NCT02507570 2019-03-19

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Phase 2 Completed

40 enrolled

Genitourinary

Prostate Carcinoma Metastatic to the Bone

NCT01929655 2018-04-24

Japanese BAY88-8223 Monotherapy Phase II Study

Phase 2 Completed

49 enrolled

Genitourinary

Prostatic Neoplasms

NCT02097303 2018-02-01

eRADicAte

Phase 2 Completed

36 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Phase 2 Completed

64 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01070485 2014-06-25

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

Phase 2 Completed

23 enrolled

Breast

Breast Neoplasms

Clinical Trials

RROPE

EXCAAPE

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

BAY88-8223, Dose Finding Study in Patients With HRPC

BAY88-8223, Does Response Study in HRPC Patients

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

RAD-THYR

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Japanese BAY88-8223 Monotherapy Phase II Study

eRADicAte

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease